Feike Jeffrey L. 4
4 · Tevogen Bio Holdings Inc. · Filed Jul 10, 2026
Research Summary
AI-generated summary of this filing
Tevogen (TVGN) Director Jeffrey L. Feike Receives 40,000-Share Award
What Happened
Jeffrey L. Feike, a director of Tevogen Bio Holdings, was granted 40,000 restricted shares on 2026-07-10. The shares were reported as acquired at $0.00 (no cash exchanged), so the immediate reported value is $0. This is an equity award (compensation), not an open-market purchase or sale.
Key Details
- Transaction date: 2026-07-10. Grant type: Award/Grant (code A). Reported acquisition price: $0.00. Shares granted: 40,000.
- Shares owned after the transaction: Not disclosed in this filing.
- Footnote: The grant is restricted stock under Tevogen’s 2024 Omnibus Incentive Plan. Vesting occurs in three equal installments tied to both anniversary dates (1st, 2nd, 3rd) and company revenue milestones (aggregate revenue of $50M, $100M, and $150M since the grant date), and requires the reporting person to remain in service on each vesting date.
- Filing timeliness: Report filed on 2026-07-10 (same day as the period of report), indicating a timely disclosure.
Context
This is a standard restricted stock grant used for director compensation. Because vesting depends on revenue targets and continued service, the award may be forfeited if those conditions are not met. Grants at $0 are common for compensation and do not imply an immediate cash value or market sale.
Insider Transaction Report
Form 4
Feike Jeffrey L.
Director
Transactions
- Award
Common Stock
[F1]2026-07-10+40,000→ 56,435 total
Footnotes (1)
- [F1]Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which vests in three equal installments upon the earlier of each of (i) the first anniversary of the grant date and the Issuer having aggregate revenue of $50 million since the grant date, (ii) the second anniversary of the grant date and the Issuer having aggregate revenue of $100 million since the grant date, and (ii) the third anniversary of the grant date and the Issuer having aggregate revenue of $150 million since the grant date, provided that the reporting person remains in service with the Issuer on the applicable vesting date.
Signature
/s/ Kirti Desai, Attorney-in-Fact|2026-07-10